About Magellan Diagnostics
Magellan Diagnostics is a company based in Billerica (United States) founded in 1968 was acquired by Meridian Bioscience in March 2016. Magellan Diagnostics has raised $34 million across 3 funding rounds from investors including Meridian Bioscience, NIH and Abingworth. Magellan Diagnostics offers products and services including LeadCare II, LeadCare Plus, LeadCare Ultra, and Analytical Services. Magellan Diagnostics operates in a competitive market with competitors including Baseline Health, Oligoscan, Beaufort Bar and ToxTest, among others.
- Headquarter Billerica, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Meridian Bioscience, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34 M (USD)
in 3 rounds
-
Latest Funding Round
$16 M (USD), Debt – Conventional
Nov 29, 2006
-
Investors
Meridian Bioscience
& 9 more
-
Employee Count
Not available
-
Acquired by
Meridian Bioscience
(Mar 24, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Magellan Diagnostics
Magellan Diagnostics offers a comprehensive portfolio of products and services, including LeadCare II, LeadCare Plus, LeadCare Ultra, and Analytical Services.
CLIA-waived device for quick lead exposure detection in practices.
Solution for labs with smaller testing volumes and control features.
High-throughput system for convenient lead testing in high-volume settings.
Support for lead analysis and reporting to aid health risk management.
Funding Insights of Magellan Diagnostics
Magellan Diagnostics has successfully raised a total of $34M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $16 million completed in November 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Magellan Diagnostics
Magellan Diagnostics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Meridian Bioscience, NIH and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
|
Locked | Locked | Locked |
Investor details for Magellan Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Magellan Diagnostics
Investment portfolio details for Magellan Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Magellan Diagnostics
Detailed financials for Magellan Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Magellan Diagnostics Comparisons
Peer comparison for Magellan Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Magellan Diagnostics
Magellan Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Baseline Health, Oligoscan, Beaufort Bar and ToxTest, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develops test kits for diagnosing body toxins to promote health monitoring.
|
|
| Locked | Locked | Locked |
Develops innovative diagnostic devices for screening physiological imbalances.
|
|
| Locked | Locked | Locked |
Provides diagnostic tests for detecting lead poisoning to ensure public health safety.
|
|
| Locked | Locked | Locked |
Offers DIY urine tests for detecting 11 heavy metals in the body.
|
Detailed competitors of Magellan Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Magellan Diagnostics
Complete news archive for Magellan Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Magellan Diagnostics
Magellan Diagnostics was founded in 1968 and raised its 1st funding round 37 years after it was founded.
Magellan Diagnostics is headquartered in Billerica, United States. It is registered at Billerica, Massachusetts, United States.
Magellan Diagnostics is a funded company, having raised a total of $34M across 3 funding rounds to date.
Magellan Diagnostics develops point-of-care diagnostic platforms for heavy metal toxicity. The company was formerly known as ESA, Inc. and was founded by four PhD graduates from the Massachusetts Institute of Technology. It has three microfluidics-based platforms for lead testing at the point-of-care. The bench top analyzer for the measurement of lead in blood is based on Anodic Stripping Voltammetry (ASV). In addition, it also provides heavy metal toxicity testing services via its reference laboratory.
Magellan Diagnostics's top competitors include Baseline Health, Oligoscan and Beaufort Bar.
Magellan Diagnostics offers LeadCare II, LeadCare Plus, LeadCare Ultra, and Analytical Services.
Magellan Diagnostics has 10 investors. Key investors include Meridian Bioscience, NIH, Abingworth, Tekla Capital Management, and NewStar Financial.